Eris Lifesciences Limited has informed the Exchange regarding 'Revision in Outcome of Board Meeting'.
ERIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Eris Lifesciences has resubmitted its consolidated financial results for Q4 and FY25 (year ended March 31, 2025) to fix a printing error where a row for 'Capital Work in Progress' under Non-Current Assets was inadvertently hidden. The company clarified that this correction does not impact profits, total equity, or total assets. For FY25, total revenue from operations grew about 44% YoY to Rs 2,893.64 Crore (vs Rs 2,009.15 Crore), but net profit declined roughly 5.7% to Rs 374.67 Crore (vs Rs 397.12 Crore) due to sharply higher finance costs (Rs 231.29 Crore, up ~173%) and depreciation following recent acquisitions. Q4 FY25 revenue rose about 28% to Rs 705.30 Crore with net profit of Rs 102.35 Crore. Auditor Deloitte Haskins & Sells LLP issued an unmodified (clean) opinion, and prior period figures were restated following the finalization of purchase price allocation for the Swiss Parenterals acquisition.
The resubmission is purely a presentational fix with no change to bottom-line numbers, so the underlying business story is unchanged. Investors should note the strong top-line growth but margin compression from acquisition-related costs and higher interest burden. The clean auditor opinion and positive operating cash flow of Rs 1,065 Crore are positives for shareholders.